Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals Inc.

World Rank (Jan-05-2024)
8,087
Market Cap (Jan-05-2024)
1.106 Billion USD
World Rank (Jul-30-2023)
5,954
Market Cap (Jul-30-2023)
1.885 Billion USD
World Rank (Jan-07-2022)
4,662
Market Cap (Jan-07-2022)
3.161 Billion USD
World Rank (Jan-01-2021)
5,292
Market Cap (Jan-01-2021)
2.109 Billion USD
Headquarters Country
USA
Nasdaq / NYSE Code
ZNTL
Market Cap (Mar-08-2026)
0.17
Employee Count
62
Employee Count as of Date
As of 2020
Headquarters City/State
New York
World Region
Americas
World Subregion
Northern America
Annual Revenue in USD
0 Million USD
Annual Operating Income in USD
-227 Million USD
Annual Net Income in USD
-236 Million USD
Annual Results for Period Ending
Dec-2022 ending year
Total Assets in USD
539 Million USD
Total Liabilities in USD
105 Million USD
Total Equity in USD
434 Million USD
Balance Sheet for Period Ending
Dec-2022 ending year
Business Sector
Healthcare
Biopharmaceutical
Biotechnology
Company Website
ZENTALIS PHARMACEUTICALS, INC.
Yahoo
Yahoo @ Nasdaq
Company Profile
Zentalis Pharmaceuticals is a Clinical Stage Biopharmaceutical company. It is discovery and development of small molecule therapeutics targeting fundamental biological pathways of cancer. The headquarters is in USA.
Facts About Company
The company annual revenue is 7.1 million USD and 71 employees as on 2020.
Founded Year
2014
IPO Year
2020
Stock Exchange
Nasdaq
Nasdaq Sector
Health Care
Nasdaq Industry
Biotechnology: Pharmaceutical Preparations

Share